Skip to main content
European Insurance and Occupational Pensions Authority

Search QAs

Filter by

Search QAs (2169)

RSS
Showing results 2150 to 2160

1619

Can EIOPA provide practical examples for appropriate product testing?

1620

Are manufacturers expected to rectify any circumstances that could have an adverse effect for customers?

1621

In which intervals are manufacturers of insurance products expected to review their products?

1616

Are manufacturers of insurance products expected to identify the target market where insurance products are targeted to legal persons?

1617

How would the Product Oversight and Governance requirements apply in the context of group insurance contracts?

1618

What action are manufacturers expected to take if products are distributed to customers outside of the target market? Examples of appropriate action?

1615

Are manufacturers of insurance products expected to apply the Product Oversight and Governance requirements with regard to insurance products which are distributed by ancillary insurance intermediaries exempted from the scope of the IDD?

1614

How can the manufacturer demonstrate that they have taken into account the level of information available to customers and the financial literacy of customers?

1612

Can EIOPA provide more guidance on how to assess the granularity of the target market?

1903

For investments in private equity funds there is normally not possible to report Quantity in C0130, S.06.02 List of assets. Can it be wise to report just 1.0 in C0130/Quantity or should the cell be left empty?